SI-BONE SIBN 深 滬
已收盤 02-06 16:00:00 美东时间
15.59
-0.130
-0.83%
華盛通- 最 高15.83
- 今 開15.77
- 成交量 41.32万股
- 最 低 15.43
- 昨 收 15.72
- 總市值 6.76亿
- 52周最高 21.89
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 12.495
- 委 比 -43.09%
- 總股本 4339.13万
- 歷史最高 37.21
- 量 比 1.10
- 振 幅 2.54%
- 歷史最低 7.20
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SI-BONE Inc. kündigt Veröffentlichung neuer Finanzergebnisse an
SI-BONE Inc. kündigt Veröffentlichung neuer Finanzergebnisse an SI-BONE Inc. wird die Finanzzahlen für das vierte Quartal und das Gesamtjahr 2025 am 23. Februar 2026 nach Börsenschluss veröffentlichen. Die Ergebnisse werden im Bereich "Investors" auf der Unternehmenswebsite unter https://www.si-bone
02-03 05:30
SI-BONE Inc. to Report Fourth-Quarter and Full-Year Financial Results
SI-BONE Inc. to Report Fourth-Quarter and Full-Year Financial Results SI-BONE Inc. will report its fourth-quarter and full-year 2025 financial results after market close on February 23, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can reg
02-03 05:30
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
TD Cowen Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $21
TD Cowen analyst Mathew Blackman initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $21.
01-27 21:45
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings Jan 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMETEK, Stryker and Zimmer Biomet Holdings, on Tuesday. HIGHLIGHTS * AMETEK AME.N : Oppenheimer cuts to
01-27 15:49
SI-BONE shares are trading lower. The company announced Q4 and FY25 preliminary revenue results.
SI-BONE shares are trading lower. The company announced Q4 and FY25 preliminary...
01-13 02:36
SI-BONE Reports Preliminary Q4 Global Revenue Between $56.2M - $56.3M, 2025 Global Revenue Between $200.8M - $200.9M
SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash
01-12 22:01
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE reported its preliminary financial results for Q4 and FY 2025. Global revenue for FY 2025 is expected to be $200.8 to $200.9 million, representing a ~20% increase. Q4 revenue is ~$56.2 - $56.3 million, with ~15% growth. U.S. revenue grew ~21% for FY 2025 and ~14% for Q4, reaching $190.9 - $191.0 million and $53.3 - $53.4 million respectively. Active U.S. physicians increased by ~18% to ~1,640. Cash and equivalents were ~$147.7 million, wi...
01-12 14:00
Why Did SI-Bone (SIBN) Surge Spike After Hours?
SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.
01-07 14:53
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
